Experience with onabotulinumtoxinA (BOTOX) in chronic refractory migraine: Focus on severe attacks

Journal of Headache and Pain

Volumn 12, Issue 2, 2011, Pages 235-238

  Oterino, A ^a   Ramon C ^b   Pascual, J ^b  

^a HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

^b HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

Author keywords

Chronic migraine; Chronic refractory migraine; OnabotulinumtoxinA

Indexed keywords

AMITRIPTYLINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BOTULINUM TOXIN A; CANDESARTAN; FLUNARIZINE; SUMATRIPTAN; TOPIRAMATE; TRIPTAN DERIVATIVE; VALPROIC ACID; ZONISAMIDE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL PRACTICE; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE INCREASE; DRUG EFFECT; DRUG HYPERSENSITIVITY; DRUG RESPONSE; EMERGENCY TREATMENT; FACE ASYMMETRY; FEMALE; HUMAN; MALE; MIGRAINE; NECK PAIN; OPEN STUDY; PRIORITY JOURNAL; REFRACTORY PERIOD; SIDE EFFECT; TRANSFORMED MIGRAINE;

ADULT; AGED; BOTULINUM TOXINS, TYPE A; CHRONIC DISEASE; FEMALE; HEADACHE DISORDERS; HUMANS; MALE; MIDDLE AGED; MIGRAINE DISORDERS; NEUROMUSCULAR AGENTS; PAIN MEASUREMENT; PAIN, INTRACTABLE; SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

EID: 79958101815     PISSN: 11292369     EISSN: 11292377     Source Type: Journal    
DOI: 10.1007/s10194-011-0294-8     Document Type: Article

References (20)

1. Olesen J, Bousser MG, Diener HC, et al (2006) New appendix criteria open for a broader concept of chronic migraine. Cephalalgia 26:742-746
2. Castillo J, Muñoz P, Guitera V, Pascual J (1999) Epidemiology of chronic daily headache in the general population. Headache 39:190-196
3. Jensen R, Stovner LJ (2008) Epidemiology and comorbidity of headache. Lancet Neurol 7:354-361 (Pubitemid 351380536)
4. Pascual J, Sánchez del Río M, Jiménez- Hernández MD et al (2010) La migraña crónica vista por el neurólogo y el paciente. Rev Neurol 50:705-710
5. Colás R, Muñoz P, Temprano R, Gómez C, Pascual J (2004) Chronic daily headache with analgesic overuse: epidemiology and impact on quality of life. Neurology 62:1338-1342 (Pubitemid 38526046)
6. Giopponi S, Venturelli E, Rao R, Liberini P, Padovani A (2010) Hypertension is a factor associated with chronic daily headache. Neurol Sci 31(Suppl 1):S171-S173
7. Kruit MC, van Buchem MA, Launer LJ, Terwindt GM, Ferrari MD (2010) Migraine is associated with an increased risj of deep white matter lesions, subclinical posterior circulation infacts and brain iron accumulation: the population-based MRI CAMERA study. Cephalalgia 30:129-136
8. Diener HC, Bussone G, Van Oene JC, Lahaye M, Schwalen S, Goadsby PJ (2007) Topiramate reduces headache days in chronic migraine: a randomized, double-blind, placebo-controlled study. Cephalalgia 27:814-823 (Pubitemid 46961730)
9. Silberstein SD, Lipton RB, Dodick DW (2007) Efficacy and safety of topiramate for the treatment of chronic migraine. A randomized, double-blind, placebo-controlled trial. Headache 47:170-180
10. Schulman EA, Lake AE III, Goadsby PJ et al (2008) Defining refractory migraine and refractory chronic migraine: proposed criteria from the refractory headache special interest section of the American Headache Society. Headache 48:778-782 (Pubitemid 351792744)
11. Diener HC, Dodick DW, Aurora SK et al (2010) OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial. Cephalalgia 30:804-814
12. Aurora SK, Dodick DW, Turkel CC et al (2010) OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial. Cephalalgia 30:793-803
13. Dodick DW, Turkel CC, DeGryse RE et al (2010) OnabotulinumtoxinA for the treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program. Headache 50:921-936
14. Silberstein S, Tfelt-Hansen P, Dodick DW et al (2008) Guidelines for controlled trials of prophylactic treatment of chronic migraine in adults. Cephalalgia 28:484-495 (Pubitemid 351502554)
15. Silberstein S, Mathew N, Saper J, Jenkins S, Group for the BOTOX Migraine Clinical Research Group (2000) Botulinum toxin type A as a migraine preventive treatment. Headache 40:445-450 (Pubitemid 30421875)
16. Farinelli I, Coloprisco G, De Filippis S, Marteletti P (2006) Longterm benefits of botulinum toxin type A (BOTOX) in chronic daily headache: a five-year long experience. J Headache Pain 7:407-412 (Pubitemid 46085245)
17. Freitag FG, Diamond S, Diamond M, Urban G (2008) Botulinum toxin type A in the treatement of chronic migraine without medication overuse. Headache 48:201-209 (Pubitemid 351192876)
18. Mathew NT, Frishberg BM, Gawel M, Dimitrova R, Gibson J, Turkel C, the BOTOC CDH Study Group (2005) Botulinum toxin type A for the prophylaxis of chronic daily headache: a randomized, double-blind, placebo-controlled trial. Headache 45:293-307 (Pubitemid 40530193)
19. Silberstein SD, Stark SR, Lucas SM, Christie SN, DeGryse ER, Turkel CC, BoNTA-039 Group (2005) Botulinum toxin type A for the prophylactic treatment of chronic daily headache: a randomized, double-blind, placebo-controlled trial. Mayo Clin Proc 80:1126-1137 (Pubitemid 41233350)
20. Dodick DW, Mauskop A, Elkind AH, DeGryse R, Brin MF, Silberstein SD (2005) Botulinum toxin type A for the prophylaxis of patients not receiving other prophylactic medications: a randomized double-blind, placebo-controlled study. Headache 45:315-324 (Pubitemid 40530195)